Brazilian Journal of Otorhinolaryngology · 2017 · 14 citations · 15 references
MedicineOncologySurgeryEndocrine OncologyOncologic SurgerySurgical OncologyMalignant NeoplasmsRadioiodine TherapyThyroid CancerThyroid DisordersThyroid EndocrinologyThyroid SurgeryAdjuvant Radioiodine TherapyDifferentiated Thyroid Carcinoma SurgeryDisease-free Survival AssessmentHürthle Cell CarcinomaHürthle Cell LesionsPapillary Thyroid Carcinoma SurgerySurvival RatesThyroid-stimulating Hormone Suppression Therapy
INTRODUCTION: Increased body mass index is known to be associated with the high prevalence of differentiated thyroid cancers; however data on its impact on survival outcome after thyroidectomy and adjuvant therapy is scanty. OBJECTIVE: We aimed to evaluate the impact of body mass index on overall survival and disease free survival rates in patients with differentiated thyroid cancers. METHODS: (morbid obese). Various demographic, clinical and treatment characteristics and related toxicity and outcomes (overall survival, and disease free survival) were analyzed and compared. RESULTS: seen in 58 patients (27.8%). A total of 18 locoregional recurrences (8.6%) and 12 distant metastasis (5.7%) were seen. The 10 year disease free survival and overall survival rates were 83.1% and 58.0% respectively. No significant impact of body mass index on overall survival or disease free survival rates was found (p=0.081). Similarly, multivariate analysis showed that body mass index was not an independent prognostic factor for overall survival and disease free survival. CONCLUSION: Although body mass index can increase the risk of thyroid cancer, it has no impact on treatment outcome; however, further trials are warranted.
15
Jeffrey M. Friedman · Nature · 2000 · 705 citations · Full text
Mansour M. Al-Nozha, Y. Y. Al-Mazrou, Mohammed A. Al-Maatouq et al. · Saudi Medical Journal · 2005 · 305 citations
Rossella Elisei, Eleonora Molinaro, Laura Agate et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 224 citations · Full text